Roivant Sciences (NASDAQ:ROIV) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Key Points

• Jefferies raised Roivant Sciences’ price target to $52 from $42 and maintained a “buy” rating, implying 24.63% upside from the prior close. Analysts overall rate the stock “Moderate Buy,” with a consensus target of $37.14.
• Roivant shares rose 19.5% to $41.73, near their 52-week high of $42.09. The company’s latest quarterly loss of $0.26 per share was better than expected, although revenue of $1.44 million fell short of estimates.
• Insiders sold more than 3.05 million shares worth $107.3 million over the past 90 days, including sales by the CEO and another insider. Institutional investors remain significant shareholders, owning 64.76% of the stock.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) had its price objective upped by stock analysts at Jefferies Financial Group from $42.00 to $52.00 in a research note issued on Tuesday, MarketBeat.com reports. The brokerage presently has a "buy" rating on the stock. Jefferies Financial Group's price objective would indicate a potential upside of 24.63% from the company's previous close.

Other equities analysts have also recently issued research reports about the stock. Sanford C. Bernstein raised shares of Roivant Sciences to a "strong-buy" rating in a report on Wednesday, July 29th. Bank of America restated a "neutral" rating on shares of Roivant Sciences in a research report on Friday, July 31st. Piper Sandler reissued an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a report on Tuesday, August 25th. Finally, HC Wainwright reissued a "buy" rating and issued a $41.00 price target on shares of Roivant Sciences in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Roivant Sciences has an average rating of "Moderate Buy" and a consensus price target of $37.14.

Roivant Sciences Stock Up 19.5%

Shares of ROIV traded up $6.79 during trading on Tuesday, reaching $41.73. The company's stock had a trading volume of 10,572,013 shares, compared to its average volume of 6,163,936. The company has a market cap of $30.14 billion, a price-to-earnings ratio of -78.56 and a beta of 1.12. The company has a fifty day moving average of $35.30 and a two-hundred day moving average of $31.26. Roivant Sciences has a twelve month low of $12.90 and a twelve month high of $42.09.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. As a group, equities analysts forecast that Roivant Sciences will post -2 EPS for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the transaction, the chief executive officer owned 1,599,154 shares of the company's stock, valued at $57,201,738.58. This trade represents a 11.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction on Friday, August 21st. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88. Following the completion of the transaction, the insider owned 18,630,739 shares in the company, valued at $679,649,358.72. This trade represents a 0.77% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,055,913 shares of company stock worth $107,261,258 in the last 90 days. 8.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently modified their holdings of ROIV. SBI Securities Co. Ltd. grew its position in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock worth $27,000 after purchasing an additional 1,166 shares during the last quarter. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Kestra Advisory Services LLC bought a new position in Roivant Sciences during the 4th quarter valued at about $47,000. Parallel Advisors LLC raised its stake in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock valued at $57,000 after acquiring an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC raised its position in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company's stock valued at $59,000 after purchasing an additional 2,665 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.